levodopa has been researched along with Infections, Helicobacter in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aureli, F; Bhidayasiri, R; Campagnolo, M; Chung-Faye, G; Falup-Pecurariu, C; Jenner, P; Klingelhoefer, L; Leta, V; Levent, HÇ; Longardner, K; Metta, V; Ray Chaudhuri, K; Stocchi, F; Warnecke, T | 1 |
| Isaacson, SH; Pahwa, R; Pfeiffer, RF | 1 |
| Hellström, PM; Nyholm, D | 1 |
| Chen, Q; Li, M; Lin, W; Zhang, X; Zhong, R | 1 |
| Lolekha, P; Sriphanom, T; Vilaichone, RK | 1 |
| Nyholm, D; Rahne, KE; Tagesson, C | 1 |
| Azmin, S; Hashim, H; Ibrahim, NM; Manaf, MR; Razlan, H; Tan, HJ; Yahya, NW | 1 |
| Bland, JM; Castelli, V; Fiorini, G; Hughes, E; Vaira, D | 1 |
| Jeon, SH; Lee, WY; Rhee, PL; Shin, HY; Yoon, WT | 1 |
| Lyte, M | 1 |
| Ben-Shlomo, Y; Breen, K; Clarke, CE; Ives, N; Patel, S; Rees, K; Stowe, R | 1 |
| Bjarnason, I; Charlett, A; Dobbs, RJ; Dobbs, SM; Iguodala, O; Lawson, AJ; Smee, C; Taylor, D; Weller, C | 1 |
| Bergamaschi, A; Bernardi, G; Brusa, L; Fedele, E; Galante, A; Galati, S; Lunardi, G; Magrini, A; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P; Stefani, A | 1 |
| Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR | 1 |
| Fiddian-Green, RG | 1 |
| Randhir, R; Shetty, K | 1 |
| Berrutti, M; Fagoonee, S; Pellicano, R; Rizzetto, M; Saracco, G | 1 |
| Armengol, JR; Borruel, N; Casellas, F; de Torres, I; Lopez, J; Malagelada, JR; Saperas, E; Vergara, M | 1 |
| Fedele, E; Frasca, S; Galante, A; Giacomini, P; Lunardi, G; Marciani, MG; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P | 1 |
| Fedele, E; Galante, A; Giacomini, P; Lunardi, G; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P | 1 |
7 review(s) available for levodopa and Infections, Helicobacter
| Article | Year |
|---|---|
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
Topics: Antiparkinson Agents; Gastrointestinal Tract; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2023 |
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Gastritis; Gastroparesis; Helicobacter Infections; Humans; Levodopa; Parkinson Disease; Peptic Ulcer | 2020 |
Effects of Helicobacter pylori on Levodopa Pharmacokinetics.
Topics: Dopamine Agents; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2021 |
Helicobacter pylori infection is associated with a poor response to levodopa in patients with Parkinson's disease: a systematic review and meta-analysis.
Topics: Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2022 |
A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy.
Topics: Adolescent; Adult; Aged; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Iron Compounds; Levodopa; Male; Middle Aged; Remission Induction; Thyroxine; Treatment Outcome; Young Adult | 2015 |
Helicobacter pylori eradication for Parkinson's disease.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2011 |
Helicobacter pylori and dementia. Which consistency for an association?
Topics: Absorption; Animals; Dementia; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; MEDLINE; Models, Biological | 2007 |
5 trial(s) available for levodopa and Infections, Helicobacter
| Article | Year |
|---|---|
Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antiparkinson Agents; Breath Tests; Clarithromycin; Comorbidity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index | 2008 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; Double-Blind Method; Dyspepsia; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Metronidazole; Omeprazole; Peptic Ulcer; Sucrose; Tetracycline; Treatment Outcome | 2006 |
The impact of delaying gastric emptying by either meal substrate or drug on the [13C]-urea breath test.
Topics: Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Isotopes; Dopamine Agents; Duodenal Ulcer; Female; Food, Formulated; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Premedication; Reproducibility of Results; Sensitivity and Specificity; Stomach Ulcer; Time Factors; Urea; Water | 1999 |
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Drug Therapy, Combination; Helicobacter Infections; Humans; Intestinal Absorption; Levodopa; Omeprazole; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2001 |
8 other study(ies) available for levodopa and Infections, Helicobacter
| Article | Year |
|---|---|
Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial).
Topics: Aged; Anti-Bacterial Agents; Antiparkinson Agents; Breath Tests; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Quality of Life | 2021 |
Motor fluctuations and Helicobacter pylori in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Breath Tests; Female; Folic Acid; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Absorption; Levodopa; Male; Parkinson Disease; Treatment Outcome; Vitamin B 12 | 2013 |
Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Biological Availability; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Parkinson Disease | 2010 |
Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiparkinson Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypokinesia; Intestine, Small; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinsonian Disorders; Treatment Outcome | 2013 |
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.
Topics: Aged; Anti-Bacterial Agents; Comorbidity; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebo Effect; Treatment Outcome | 2006 |
Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
Topics: Antiparkinson Agents; Brain; Cytokines; Dyskinesia, Drug-Induced; Endotoxins; Energy Metabolism; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Levodopa; Parkinson Disease | 2007 |
Improved alpha-amylase and Helicobacter pylori inhibition by fenugreek extracts derived via solid-state bioconversion using Rhizopus oligosporus.
Topics: alpha-Amylases; Anti-Ulcer Agents; beta-Glucosidase; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Hypoglycemic Agents; Levodopa; Oxidation-Reduction; Phytotherapy; Plant Extracts; Rhizopus; Superoxide Dismutase; Time Factors; Trigonella | 2007 |
Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Malabsorption Syndromes; Middle Aged; Parkinson Disease | 2001 |